Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mesoblast Ltd ADR (MESO)

Mesoblast Ltd ADR (MESO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 17.23 (+17.77%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 17.23 (+17.77%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 17.23 (+17.77%)
Why Shares of Mesoblast Are Down Monday

The company's shares continued to tumble after it received a Complete Response Letter last week from the FDA.

MSB.AX : 2.550 (+0.79%)
MESO : 17.23 (+17.77%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 17.23 (+17.77%)
Why Shares of Mesoblast Are Plunging Friday

The company received a Complete Response Letter from the FDA regarding its prospective graft-versus-host disease therapy.

MSB.AX : 2.550 (+0.79%)
MESO : 17.23 (+17.77%)
Appendix 4C Quarterly Activity Report

Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022...

MSB.AX : 2.550 (+0.79%)
MESO : 17.23 (+17.77%)
Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management

NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

MSB.AX : 2.550 (+0.79%)
MESO : 17.23 (+17.77%)
Mesoblast Key Opinion Leader Event Series for Investors & Analysts

Chronic Low Back Pain due to Degenerative Disc Disease...

MSB.AX : 2.550 (+0.79%)
MESO : 17.23 (+17.77%)
Operational Highlights and Financial Results for the Period Ended March 31, 2022

Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission...

MSB.AX : 2.550 (+0.79%)
MESO : 17.23 (+17.77%)

Barchart Exclusives

1 Penny Stock Wall Street Expects to Soar 100% in 2025
This penny stock is making its way through the artificial intelligence wave. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar